Topic:

R&D

Latest Headlines

Latest Headlines

Which vehicle works best? High-speed testing gives drug delivery a boost

Finding the right delivery vehicle for a drug, one that will let the drug reach its full potential, is an invaluable prospect. And now MIT engineers have developed a way to test these vehicles quickly in vivo to determine which of them will be most efficient in delivering its payload.

Sanofi sets up a major R&D hub in booming Shanghai

French pharma giant Sanofi has unveiled plans to bring together the drug development work being done in a dozen different Pacific Rim countries, creating a major new R&D center in Shanghai that will employ 1,400 staffers.

Portola's 'breakthrough' anti-anticoagulant clears a Phase III hurdle

Portola Pharmaceuticals' antidote to Big Pharma's latest crop of blockbuster blood thinners hit the mark in its first Phase III trial, clearing the way for an FDA submission next year.

Alnylam launches study to support its rare disease candidate ALN-AS1

RNAi leader Alnylam, the American Porphyria Consortium and The European Porphyria Network are launching the Explore observational study of patients with the rare disease, with the hope of advancing Alnylam's candidate for porphyria, with a goal of filing for approval in late 2014 or early 2015. 

FibroGen lines up a $125M IPO to shoulder its way into the IPF race

Flush with cash from its high-profile collaborators, FibroGen is plotting a $120 million IPO to help bankroll a stable of unpartnered drugs, including a promising lung treatment with huge market potential.

Flagging Novartis drops out of hep C race, punting a $440M Enanta pact

According to the biotech Enanta, you can count Novartis out of the race to develop next-gen hepatitis C cocktails. The pharma giant has bowed out of its partnership with Enanta on an NS5A inhibitor code-named EDP-239, which attracted a $440 million deal--including $36 million upfront--back in 2012.

GlaxoSmithKline deepens its commitment to 'electroceuticals'

GlaxoSmithKline is expanding its efforts to encourage research into bioelectronic medicine, putting up $5 million to support R&D projects around the world.

J&J makes a splash in hep C with a $1.75B deal for Alios

Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.

Regeneron's would-be blockbuster completes the allergic circle with Phase II success

Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions.

Study: Publicly available information about 510(k) devices' safety and effectiveness lacking

A study published Sept. 29 in The Journal of the American Medical Association concluded that publicly available information to support the safety and effectiveness of implanted, 510(k)-cleared devices is lacking.